Gingivostomatitis is a contagious mouth infection, which causes painful sores, blisters, and swelling in the tongue and uvula. It usually spreads through the saliva of an infected individual or by direct contact with a lesion or sore. Gingivostomatitis is also called as herpetic, which is caused by herpes simplex virus and is the most common cause of gingivostomatitis. Gingivostomatitis is the most common among young children, usually under 6 years old, but it may also occur in adults. Geriatric people may experience severe symptoms than adults and children.
Market Dynamics
Rising incidence of gingivostomatitis caused by herpes simplex virus (HSV) is expected to drive the chronic gingivostomatitis treatment market growth. For instance, according to the International Journal of Dentistry, an article published in October 2016, reports that over 90% of gingivostomatitis cases are caused by herpes simplex virus (HSV) type 1 and the remainder are caused by herpes simplex virus (HSV) type 2.
However, lack of identification or diagnosis of chronic gingivostomatitis are expected to hinder the market growth. For instance, according to the Journal of Dental Health Oral Disorders & Therapy, an article published in 2017, states that chronic gingivostomatitis may be asymptomatic in some instances, may be unnoticed in some instances, and sometimes get misdiagnosed with other chronic mouth ulcers.
Key features of the study:
- This report provides in-depth analysis of the global chronic gingivostomatitis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global chronic gingivostomatitis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global chronic gingivostomatitis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic gingivostomatitis treatment market
Detailed Segmentation:
- Global Chronic Gingivostomatitis Treatment Market, By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- Global Chronic Gingivostomatitis Treatment Market, By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- Global Chronic Gingivostomatitis Treatment Market, By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- Global Chronic Gingivostomatitis Treatment Market, By Region:
- North America
- By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- By Country:
- Latin America
- By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type:
- By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
- By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
- By End User:
- Hospitals & Clinics
- Academic & Research
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Taj Pharmaceutical limited.
- Ciron pharma
- Johnson & Johnson
- GlaxoSmithKline PLC
- Merck & CO., Inc.
- Novartis AG
- Hoffman La Roche AG
- Eli Lily and Company
- AstraZeneca Plc.
“*” marked represents similar segmentation in other categories in the respective section.
